NCT04672356View on ClinicalTrials.gov

A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 25, 2021

Primary Completion Date

January 1, 2023

Study Completion Date

June 1, 2023

Conditions

Advanced Lung Cancer

Interventions

BIOLOGICAL

IBI939

IBI939 injection

BIOLOGICAL

Sintilimab

Sintilimab injection

Trial Locations (1)

Unknown

Jilin Province Cancer Hospital, Jilin

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT04672356 - A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer | Biotech Hunter | Biotech Hunter